Svenska Dokumentmallar
MDR Article 88 – Trend Reporting, Supply Analysis and CAPA Register | Word/PDF/Excel
MDR Article 88 – Trend Reporting, Supply Analysis and CAPA Register | Word/PDF/Excel
- File format
- DOCX, PDF, XLSX
- Document language
- Five Swedish operational templates and a Swedish user guide in DOCX/PDF; separate English User Guide in DOCX/PDF; Swedish Excel workbook with nine tabs. No full English version of the work templates.
- Number of files
- 7
Digital download. No physical product is shipped.
Couldn't load pickup availability
About this template
Pay attention to recurring offers involving medical devices – and document the difference between a frequency signal, statistical significance, and an actual reporting obligation. This document package supports MDR manufacturers, quality managers, and vigilance functions in their work with Article 88 of Regulation (EU) 2017/745. With Word, PDF, and Excel, you can follow a traceable chain from event classification and planned statistical method to a potential regulatory report, corrective actions, and verified effectiveness.
Quick facts: Swedish/EU law • five Swedish work templates, a Swedish guide, and a separate English User Guide • 7 editable DOCX + 7 searchable/printable PDFs + 1 XLSX with 9 tabs • 15 files in a digital ZIP delivery. Searchable PDFs are not interactively fillable.
Package contents
Seven document types: offer triage, trend plan with baseline, trend investigation and benefit–risk decision, regulatory reporting and evidence, CAPA/effectiveness verification, a Swedish user guide, and an English User Guide. Each document is provided in Word and searchable PDF. In addition, there is a Swedish Excel register with nine tabs. Total: 7 DOCX + 7 PDF + 1 XLSX = 15 customer files. The PDF version of a Word document is not a separate legal document.
What the files contain
Form fields for product/UDI, risk class, event ID, actual knowledge occasion, Article 87 triage, baseline, comparable exposure volume, predefined method, significance test, benefit–risk assessment, regulatory decision, and actual reporting confirmation. Excel distinguishes between recorded event, numerical signal, expert risk decision, actually submitted report, and verified CAPA effect. Nothing is sent automatically.
When might an MDR manufacturer need this package?
Example 1: A manufacturer of medical measuring instruments sees more service and user complaints. They need to distinguish changed usage volume from a genuinely increasing frequency and check whether the events are serious under Article 87 or fall under Article 88. Example 2: A manufacturer is following up on an expected adverse effect and needs a pre-defined baseline, relevant risk documentation, and a documented statistical method. Example 3: After an action, the quality function needs to show that the change actually had the intended effect, not just that a CAPA was marked as completed.
Product scope: Designed for the manufacturer's workflow under MDR 2017/745. IVD products are covered by IVDR 2017/746, with their own articles and reporting provisions. Independent distributors and healthcare providers have different roles and obligations. The template does not provide CE certification, laboratory results, independent statistical expert analysis, or regulatory approval.
All files and functions
| Document | Function | Language | Format |
|---|---|---|---|
| Offer triage – Article 87 or 88 | Assess whether a suspected serious incident must be escalated immediately. | Swedish | DOCX + searchable PDF |
| Trend plan, baseline, and method | Define product group, time period, exposure, and statistical method. | Swedish | DOCX + searchable PDF |
| Trend investigation and benefit–risk decision | Keep observed increase, significance, and legal criteria separate. | Swedish | DOCX + searchable PDF |
| Reporting decision and evidence | Document regulatory pathway, actual submission, and receipt confirmation. | Swedish | DOCX + searchable PDF |
| CAPA and effectiveness verification | Distinguish completed safety action from verified effectiveness. | Swedish | DOCX + searchable PDF |
| Swedish user guide | Seven work steps, legal references, and clear limitations. | Swedish | DOCX + searchable PDF |
| English User Guide | Instructions in English for the Swedish work templates. | English | DOCX + searchable PDF |
| Excel – trend and CAPA register | Nine tabs with baselines, offers, trends, decisions, and actions. | Swedish | XLSX |
The nine-tab Excel tool
Read me, Overview, Products, Signals, Baselines, Trends, Risk Decisions, Actions, Sources. The eight administrative compilations show, for example, registered products, received events, cases for urgent Article 87 review, trends over the entered baseline, undetermined ratios, completed expert assessments, actually submitted reports, and verified CAPA effects.
The simple trend calculation normalizes the number of events per 1,000 manually entered exposure units. The comparison gives "Above baseline – manual review", "Not above baseline – still review", or "Not assessed". The ratio is not a significance test, p-value, confidence interval, or medical device risk decision. The baseline and statistical method must be documented in the manufacturer's PMS plan/technical documentation. If the exposure denominator is zero or missing, no false sense of safety is created.
How the package is used – from offer to verified CAPA
- Immediately assess whether it may be a serious incident under MDR Article 87. If so: follow the separate urgent reporting pathway.
- Record the product, event category, risk file, relevant PMS version, and the actual knowledge occasion.
- Use the pre-planned observation period, statistical method, and product/event-specific baseline.
- Document the actual exposure denominator and any differences in reporting rate and product mix.
- Have qualified personnel assess statistical significance, the benefit–risk ratio, and whether an unacceptable risk may arise.
- If there is a reporting obligation: follow the Swedish Medical Products Agency's current instructions, and record only the actually submitted report and actual receipt as completed.
- Separate the corrective action, its implementation, and actual effectiveness verification. Update relevant PMS and risk files.
The law: MDR Articles 83, 87, 88, and 89
Articles 83 and 84: The manufacturer shall have a risk-based post-market surveillance system and a PMS plan. Article 88 requires the manufacturer to specify in the plan how affected incidents shall be handled, which method is used for a statistically significant increase, and the chosen observation period. Official consolidated MDR text in Swedish.
Article 87 – serious incidents: Serious incidents and certain corrective safety actions have a separate and urgent reporting procedure. The Swedish Medical Products Agency describes maximum timeframes of normally two, ten, or fifteen calendar days depending on the consequence and circumstances; the obligation to report may arise earlier. A suspected serious incident must not wait in an Article 88 trend queue.
Article 88 – trends: The reportable situation is not merely that the number of complaints has increased. A statistically significant increase in frequency or severity of non-serious incidents or expected adverse effects is required, which may affect the benefit–risk analysis in the prescribed manner and has led or may lead to risks that are unacceptable in relation to the intended benefit. Compare with the foreseeable frequency or severity over the period specified in the manufacturer's documentation.
Article 89: Special requirements apply to analysis and corrective safety actions after serious incidents. Creating a CAPA log does not mean that the requirements for a field safety action or reporting are thereby met.
EUDAMED 2026 – what applies to trend reporting?
The European Commission confirms that four EUDAMED modules became mandatory on 28 May 2026: actors, UDI/products, notified bodies/certificates, and market surveillance. However, the module for vigilance and post-market surveillance was still under development on 17 November 2026. The European Commission's current module list. Therefore, check the national reporting pathway and the actual system status for each case. The Excel register is never an EUDAMED or MIR form.
Personal data and statistical limitations
Use only the product and case references that are necessary. Medical device incidents may contain sensitive health data requiring special data protection under GDPR. Patient records and directly identifying information should not be placed in an unprotected workbook. Independent statistical expert validation is not included, nor is a valid Article 88 report, a regulatory submission, or a regulatory signature.
Complement with related templates
For EUDAMED registration and UDI, there is a separate product. MDR/IVDR Article 10a – supply interruption covers interruption information, not incident trends. For structured risk analysis, there is FMEA and action register. This product covers the narrower Article 88 process.
Frequently Asked Questions (FAQ)
Must all increases in complaints be reported under Article 88?
No. A relevant statistically significant increase and the other criteria in Article 88 are required, including the assessment of benefit–risk and unacceptable risk. An Excel ratio over 1 is not sufficient.
Can we handle serious incidents via the same Excel tab?
Registration can be used for traceability, but serious and potentially serious events must first be reviewed and, if necessary, reported urgently under Article 87. Trend reporting must not delay that process.
Does the workbook calculate statistical significance?
No. Excel calculates the frequency per 1,000 specified exposure units and compares it with a manually entered baseline. The statistical method, significance, and clinical risk are assessed by the manufacturer according to the PMS plan.
Does this product also apply to IVD products?
Not without adaptation. In vitro diagnostic products are regulated primarily by IVDR 2017/746 with different article numbers and special obligations.
Can Excel submit a report to EUDAMED or the Swedish Medical Products Agency?
No. No file automates a regulatory submission. Document the current channel, the actual submission date, and actual receipt confirmation when available.
Are all work documents also available in English?
No. Five Swedish operational templates, a Swedish user guide, and a separate English User Guide are included. The English guide is an instruction, not fully translated operational templates.
Are the PDF versions digitally fillable?
No. They are searchable and can be printed. DOCX or XLSX is used for editing.
Has the product been reviewed by a lawyer or medical device expert?
No. Only internal AI-assisted legal source control and technical documentation/Excel QA have been carried out. Independent legal, medical device, or statistical expert review has not been performed.
Sources and version
Version 1.0, 17 November 2026. Official sources: MDR 2017/745, Articles 83–89, Swedish Medical Products Agency – serious incidents, European Commission – EUDAMED status, MDCG guidance, and GDPR. The sources describe the rules, not a regulatory approval of this product.
